UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials

European heart journal, 2022-02, Vol.43 (7), p.e17-e25

2022

Link zum Volltext

Verfügbarkeit prüfen

The Primary Outcome Fails — What Next?

The New England journal of medicine, 2016-09, Vol.375 (9), p.861-870

2016

Link zum Volltext

Verfügbarkeit prüfen

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

The Lancet (British edition), 2007-10, Vol.370 (9596), p.1453-1457

2007

Link zum Volltext

Verfügbarkeit prüfen

Empagliflozin and Major Renal Outcomes in Heart Failure

New England Journal of Medicine, 2021-10, Vol.385 (16), p.1531-1533

2021

Link zum Volltext

Verfügbarkeit prüfen

BMI and risk of dementia in two million people over two decades: a retrospective cohort study

The lancet. Diabetes & endocrinology, 2015-06, Vol.3 (6), p.431-436

2015

Link zum Volltext

Verfügbarkeit prüfen

The Primary Outcome Is Positive — Is That Good Enough?

The New England journal of medicine, 2016-09, Vol.375 (10), p.971-979

2016

Link zum Volltext

Verfügbarkeit prüfen

Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure

Journal of the American College of Cardiology, 2021-03, Vol.77 (11), p.1397-1407

2021

Link zum Volltext

Verfügbarkeit prüfen

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies

International journal of surgery (London, England), 2014-12, Vol.12 (12), p.1495-1499

2014

Link zum Volltext

Verfügbarkeit prüfen

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

PLoS medicine, 2007-10, Vol.4 (10), p.e296-e296

2007

Link zum Volltext

Verfügbarkeit prüfen

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

The Lancet (British edition), 2020-09, Vol.396 (10254), p.819-829

2020

Link zum Volltext

Verfügbarkeit prüfen

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

Circulation (New York, N.Y.), 2021-01, Vol.143 (4), p.310-321

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies

Journal of the American College of Cardiology, 2017-01, Vol.69 (3), p.345-357

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

European heart journal, 2022-02, Vol.43 (5), p.416-426

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care

Journal of the American College of Cardiology, 2015-09, Vol.66 (11), p.1273-1285

2015

Link zum Volltext

Verfügbarkeit prüfen

Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration

PLoS medicine, 2007-10, Vol.4 (10), p.e297-e297

2007

Link zum Volltext

Verfügbarkeit prüfen

Adaptive increase in sample size when interim results are promising: A practical guide with examples

Statistics in medicine, 2011-12, Vol.30 (28), p.3267-3284

2011

Link zum Volltext

Verfügbarkeit prüfen

Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron‐deficient heart failure patients: an individual patient data meta‐analysis

European journal of heart failure, 2018-01, Vol.20 (1), p.125-133

2018

Link zum Volltext

Verfügbarkeit prüfen

Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials

The Lancet (British edition), 2015-05, Vol.385 (9979), p.1729-1737

2015

Link zum Volltext

Verfügbarkeit prüfen

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

Circulation (New York, N.Y.), 2021-10, Vol.144 (16), p.1284-1294

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

Circulation (New York, N.Y.), 2021-01, Vol.143 (4), p.326-336

2021

Link zum Volltext

Verfügbarkeit prüfen

Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced

Journal of the American College of Cardiology, 2021-03, Vol.77 (11), p.1397-1407

2021

Link zum Volltext

Verfügbarkeit prüfen

Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies

European heart journal, 2013-05, Vol.34 (19), p.1404-1413

2013

Link zum Volltext

Verfügbarkeit prüfen

Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation

The New England journal of medicine, 2016-06, Vol.374 (23), p.2235-2245

2016

Link zum Volltext

Verfügbarkeit prüfen

The win ratio approach for composite endpoints: practical guidance based on previous experience

European heart journal, 2020-12, Vol.41 (46), p.4391-4399

2020

Link zum Volltext

Verfügbarkeit prüfen

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

The Lancet (British edition), 2009-06, Vol.373 (9681), p.2125-2135

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.050

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(973)
Mit Volltextzugriff
(974)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(617)
Life Sciences & Biomedicine
(609)
Humans
(505)
Cardiovascular System & Cardiology
(370)
Cardiac & Cardiovascular Systems
(349)
Female
(267)
Male
(265)
Aged
(215)
Middle Aged
(212)
Biological And Medical Sciences
(160)
Medical Sciences
(154)
Clinical Trials
(147)
Treatment Outcome
(147)
Mortality
(142)
Heart Failure
(134)
Cardiology
(129)
Risk Factors
(126)
Heart Attacks
(119)
Cardiovascular
(114)
General & Internal Medicine
(113)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials

The Primary Outcome Fails — What Next?

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Empagliflozin and Major Renal Outcomes in Heart Failure

BMI and risk of dementia in two million people over two decades: a retrospective cohort study

The Primary Outcome Is Positive — Is That Good Enough?

Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care

Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration

Adaptive increase in sample size when interim results are promising: A practical guide with examples

Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron‐deficient heart failure patients: an individual patient data meta‐analysis

Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced

Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies

Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation

The win ratio approach for composite endpoints: practical guidance based on previous experience

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Suchergebnisse filtern